Šeruga, Boštjan, 1973-
Boštjan Šeruga
VIAF ID: 90154440115635340429 ( Personal )
Permalink: http://viaf.org/viaf/90154440115635340429
Preferred Forms
-
100 0 _
‡a
Boštjan Šeruga
-
100 1 _
‡a
Šeruga, Boštjan,
‡d
1973-
4xx's: Alternate Name Forms (4)
Works
| Title | Sources |
|---|---|
| Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer |
|
| Adjuvant radiation therapy after radical nephrectomy in patients with localized renal cell carcinoma a systematic review and meta-analysis |
|
| Assessing women at high risk of breast cancer: a review of risk assessment models |
|
| Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. |
|
| The changing face of hormonal therapy for prostate cancer |
|
| Chemotherapy-based treatment for castration-resistant prostate cancer |
|
| Cytokines and their relationship to the symptoms and outcome of cancer. |
|
| Delivery of Global Cancer Care: An International Study of Medical Oncology Workload |
|
| Do we have to change the way targeted drugs are developed |
|
| Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. |
|
| Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. |
|
| The evolving landscape of protein kinases in breast cancer: clinical implications. |
|
| Extended adjuvant tamoxifen for early breast cancer a meta-analysis |
|
| Global drug development in cancer : a cross-sectional study of clinical trial registries |
|
| Hormonal anticancer treatment in the senior cancer patient |
|
| Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs |
|
| Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. |
|
| Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. |
|
| Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer |
|
| Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. |
|
| Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer. |
|
| Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study? |
|
| Medical Oncology Workload in Europe: One Continent, Several Worlds |
|
| Meta-Research on Oncology Trials: A Toolkit for Researchers with Limited Resources |
|
| Multidimensional challenges in clinical drug development, regulatory approval, and marketing. |
|
| Napotki za premagovanje neželenih učinkov sistemskega zdravljenja raka : kaj morate vedeti? |
|
| Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. |
|
| Osteoblastic bone metastases from renal cell carcinoma |
|
| Outcome of severe infections in afebrile neutropenic cancer patients |
|
| Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? |
|
| Post-marketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials |
|
| Prediktivni genetski testi pri zgodnjem raku dojk : vrste, razlike, indikacije |
|
| Pregled kliničnih raziskav z zaviralci CDK 4/6 |
|
| Presejanje na okužbo z virusom hepatitisa B in preprečevanje reaktivacije hepatitisa B |
|
| Pretreatment differences in intraindividual variability in reaction time between women diagnosed with breast cancer and healthy controls |
|
| Preživetje bolnikov z rakom, zbolelih v letih 1997-2016 v Sloveniji. |
|
| The price we pay for progress : a meta-analysis of harms of newly approved anticancer drugs |
|
| Primum non nocere : meta-analysis |
|
| Prognostic role of platelet to lymphocyte ratio in solid tumors : a systematic review and meta-analysis |
|
| Prognostic role of telomere length in malignancies : a meta-analysis and meta-regression |
|
| Prognostic significance of pretreatment neutrophil/-lymphocyte ratio in breast cancer a meta-analysis |
|
| Prognostični in prediktivni biomarkerji v imuno-onkologiji |
|
| Rak ledvic : ali nova odkritja zdravljenja z imunoterapijo so tudi pri raku ledvic zelo obetavna |
|
| Rak materničnega vratu : klinični primer |
|
| Rak prostate |
|
| A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer |
|
| Relevance of randomised controlled trials in oncology |
|
| Reporting of randomized trials in common cancers in the lay media |
|
| Risk of incremental toxicities and associated costs of new anticancer drugs : a meta-analysis |
|
| Role of PET in patients with advanced Hodgkin's lymphoma with residual tumor masses after chemotherapy |
|
| Should my accountant sing La Traviata at the Met? |
|
| Sunitinib in solid tumors |
|
| Survival of cancer patients, diagnosed in 1997-2016 in Slovenia |
|
| Systemic treatment of HER-positive disease |
|
| Target agents toxicity |
|
| Targeted therapies for renal cell carcinoma : more gains from using them again |
|
| Targeting DNA repair in breast cancer : a clinical and translational update |
|
| Toksičnost zaviralcev aromataze v zdravljenju zgodnjega raka dojke |
|
| Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial |
|
| Training of oncologists : results of a global survey |
|
| Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer |
|
| Under-reporting of harm in clinical trials |
|
| Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer : the emperor has no clothes |
|
| Vloga za kosti specifičnih zdravil pri rakavih bolnikih s kostnimi zasevki = Role of bone-modifying agents in treatment of cancer patients with bone metastases |
|
| Vpliv hormonskega zdravljenja raka dojk na krvno-žilni sistem |
|
| Vrednotenje koristi novih protirakavih zdravil = Evaluation of benefits of anticancer agents |
|
| Vrste onkoloških tarčnih zdravil |
|
| Zdravljenje raka požiralnika s preoperativno kemoradioterapijo : magistrsko delo |
|
| Zdravljenje z everolimusom : knjižica za bolnike |
|
| Zdravljenje z radijevim kloridom : informacije za bolnika |
|
| Živeti s kostnimi zasevki : informativna knjižica za bolnike z rakom |
|
| Zoledronic acid for breast cancer therapy-induced bone loss : medical oncology |
|
